COMMUNIQUÉS West-GlobeNewswire

-
CPC Issues Letter to Fellow XWELL, Inc. Shareholders Revealing Intention Behind Recent Schedule 13D Filing & Lawsuit Against Entrenched Board of Directors
24/07/2024 -
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
24/07/2024 -
Viemed Healthcare Announces Date and Time for Conference Call
24/07/2024 -
Helio Genomics to Participate in the 2024 UBS Genomic Medicine Summit
24/07/2024 -
The Broken Brown Egg and Progyny Announce the 2024 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building
24/07/2024 -
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
24/07/2024 -
Revolo Announces New Data Further Validating the Upstream Mechanism of Action and Subcutaneous Administration of ‘1104
24/07/2024 -
Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter
24/07/2024 -
Intelligent Bio Solutions Inc. Announces QabasTech as Exclusive Distributor in Saudi Arabia
24/07/2024 -
TOMI Environmental Solutions Secures $1.2 Million Contract with Enviro-Mist Inc. Driving SteraMist Growth in the Pharmaceutical Market
24/07/2024 -
ICU Medical Announces Time of Second Quarter 2024 Earnings Conference Call
24/07/2024 -
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
24/07/2024 -
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
24/07/2024 -
R1 RCM Special Committee Provides Update on Evaluation of Strategic Alternatives
24/07/2024 -
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
24/07/2024 -
ImPact Biotech Receives a €13.5M Investment Commitment from the European Innovation Council’s Accelerator Program
24/07/2024 -
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
24/07/2024 -
Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
24/07/2024 -
Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
24/07/2024
Pages